荟萃分析
心力衰竭
医学
疾病
内科学
重症监护医学
心脏病学
作者
Muhammad Usman,Deepak L. Bhatt,Ishaque Hameed,Stefan D. Anker,Alice Cheng,Adrian F. Hernandez,W. Schuyler Jones,Muhammad Shahzeb Khan,Mark C. Petrie,Jacob A. Udell,Tim Friede,Javed Butler
标识
DOI:10.1016/s2213-8587(24)00102-5
摘要
Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been studied in patients with heart failure, type 2 diabetes, chronic kidney disease, atherosclerotic cardiovascular disease, and acute myocardial infarction. Individual trials were powered to study composite outcomes in one disease state. We aimed to evaluate the treatment effect of SGLT2 inhibitors on specific clinical endpoints across multiple demographic and disease subgroups.
科研通智能强力驱动
Strongly Powered by AbleSci AI